WO2016119031A8 - Composto, processo de síntese do composto, uso, composição farmacêutica, método de tratamento de inflamações ou de doença neurodegenerativa, forma de dosagem oral e método de inibição de enzima acetilcolinesterase - Google Patents

Composto, processo de síntese do composto, uso, composição farmacêutica, método de tratamento de inflamações ou de doença neurodegenerativa, forma de dosagem oral e método de inibição de enzima acetilcolinesterase Download PDF

Info

Publication number
WO2016119031A8
WO2016119031A8 PCT/BR2016/050010 BR2016050010W WO2016119031A8 WO 2016119031 A8 WO2016119031 A8 WO 2016119031A8 BR 2016050010 W BR2016050010 W BR 2016050010W WO 2016119031 A8 WO2016119031 A8 WO 2016119031A8
Authority
WO
WIPO (PCT)
Prior art keywords
compound
synthetising
inflammation
pharmaceutical composition
inhibiting
Prior art date
Application number
PCT/BR2016/050010
Other languages
English (en)
French (fr)
Other versions
WO2016119031A1 (pt
Inventor
Eliezer DE JESUS LACERDA BARREIRO
Cláudio VIEGAS JÚNIOR
Flávio PEREIRA DIAS VIEGAS
Miguel DIVINO DA ROCHA
Original Assignee
Fundação De Amparo À Pesquisa Do Estado De Minas Gerais - Fapemig
Universidade Federal Do Rio De Janeiro - Ufrj
Universidade Federal De Alfenas – Unifal-Mg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from BR102015002132-1A external-priority patent/BR102015002132B1/pt
Application filed by Fundação De Amparo À Pesquisa Do Estado De Minas Gerais - Fapemig, Universidade Federal Do Rio De Janeiro - Ufrj, Universidade Federal De Alfenas – Unifal-Mg filed Critical Fundação De Amparo À Pesquisa Do Estado De Minas Gerais - Fapemig
Publication of WO2016119031A1 publication Critical patent/WO2016119031A1/pt
Publication of WO2016119031A8 publication Critical patent/WO2016119031A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D227/00—Heterocyclic compounds containing rings having one nitrogen atom as the only ring hetero atom, according to more than one of groups C07D203/00 - C07D225/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

A presente invenção descreve um novo composto, seu processo de síntese e os usos deste composto, bem como uma composição farmacêutica contendo o referido composto. Especificamente, a presente invenção revela um composto de acordo com a fórmula (I) : seu processo de síntese e composições compreendendo o referido composto. Adicionalmente, a presente invenção também descreve o uso do composto para fabricação de uma composição para o tratamento curativo ou profilático de doenças neurodegenerativas, de inflamações, além de composições anticolinesterásicas. Ainda, a presente invenção descreve métodos de tratamento envolvendo a administração do referido composto.
PCT/BR2016/050010 2015-01-29 2016-01-22 Composto, processo de síntese do composto, uso, composição farmacêutica, método de tratamento de inflamações ou de doença neurodegenerativa, forma de dosagem oral e método de inibição de enzima acetilcolinesterase WO2016119031A1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BR102015002132-1A BR102015002132B1 (pt) 2015-01-29 Composto para o tratamento de inflamações e doenças neurodegenerativas, seu processo de preparação, composição, forma de dosagem e uso
BR102015002132-1 2015-01-29

Publications (2)

Publication Number Publication Date
WO2016119031A1 WO2016119031A1 (pt) 2016-08-04
WO2016119031A8 true WO2016119031A8 (pt) 2016-09-22

Family

ID=56542061

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/BR2016/050010 WO2016119031A1 (pt) 2015-01-29 2016-01-22 Composto, processo de síntese do composto, uso, composição farmacêutica, método de tratamento de inflamações ou de doença neurodegenerativa, forma de dosagem oral e método de inibição de enzima acetilcolinesterase

Country Status (1)

Country Link
WO (1) WO2016119031A1 (pt)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5606054A (en) * 1993-12-14 1997-02-25 Merck & Co., Inc. Heterocyclic-fused lactams promote release of growth hormone
CA2487891A1 (en) * 2002-06-05 2003-12-18 Institute Of Medicinal Molecular Design, Inc. Inhibitors against the activation of ap-1 and nfat
CA2532313A1 (en) * 2003-07-16 2005-01-27 Institute Of Medicinal Molecular Design. Inc. Medicament for treatment of dermal pigmentation
ES2739814T3 (es) * 2013-06-19 2020-02-04 Univ Utah Res Found Compuestos de (3-(5-cloro-2-hidroxifenil)-1-benzoil-1H-pirazol sustituidos como inhibidores de histona desmetilasa

Also Published As

Publication number Publication date
WO2016119031A1 (pt) 2016-08-04
BR102015002132A2 (pt) 2016-08-02

Similar Documents

Publication Publication Date Title
WO2017053868A8 (en) C4-modified oleanolic acid derivatives for inhibition of il-17 and other uses
EA201692095A1 (ru) Имидазо[4,5-c]хинолин-2-оновые соединения и их применение в лечении рака
NZ724250A (en) Human plasma kallikrein inhibitors
UA86614C2 (ru) Соединение, которое имеет активность ингибитора киназ, фармацевтическая композиция, которая включает указанное соединение, и их применение для приготовления лекарственного препарата
MX368781B (es) Compuesto inhibidor de las actividades de las cinasas btk y/o jak3.
NZ726366A (en) Syk inhibitors
MX2015008957A (es) Fluoro-[1,3]oxazinas como inhibidores de beta-secretasa 1 (bace1).
MX2008013212A (es) 4-anilinquinolina-3-carboxamidas como inhibidores de la cinsa csf-1r.
PH12020550341A1 (en) Niraparib formulations
TN2019000204A1 (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
PH12015502365B1 (en) Bace1 inhibitors
EA201171088A1 (ru) Лечение дискинезии при различных расстройствах
PH12017500810A1 (en) Substituted 2,4 diamino-quinoline as new anticancer agents
WO2015104292A3 (en) Compounds for use in treating or preventing cancerous diseases
WO2018111315A8 (en) PYRIMIDINE TRICYCLIC ENONE DERIVATIVES FOR INHIBITION OF RORγ AND OTHER USES
WO2013188268A8 (en) Topical ophthalmological pharmaceutical composition containing pazopanib
MX2021010297A (es) Inhibidores de calicreina plasmatica humana.
MX2015001917A (es) Composiciones farmaceuticas de memantina.
SG10201907289VA (en) Monomethylfumarate prodrug compositions
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
MX2009007889A (es) Derivados de 3-cinnolincarboxamida y su uso para el tratamiento del cancer.
WO2017053711A3 (en) Deuterated cftr potentiators
PH12018500469A1 (en) Sulfonamide compounds as voltage-gated sodium channel modulators
MX2018002177A (es) Nuevo derivado de catecol y composicion farmaceutica que comprende el mismo.
MX2017012188A (es) Inhibidores de beta-secretasa 1 (bace1).

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16742595

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16742595

Country of ref document: EP

Kind code of ref document: A1